| BTG International Limited Patent applications |
| Patent application number | Title | Published |
|---|
| 20120095390 | Generation of Therapeutic Microfoam - Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen. | 04-19-2012 |
| 20120089083 | Apparatus for delivering foam - Apparatus, e.g. a syringe, for dispensing foam includes means for ensuring that only foam of adequate quality is dispensed. In use, the syringe may be filled from a pressurised canister which generates foam e.g. for therapeutic use in treating varicose veins. An initial quantity of foam dispensed from the canister may be of inadequate quality in which case it should not be used: the syringe includes means to ensure that this initial quantity of foam is diverted to a waste port or to an internal waste chamber e.g. located in the syringe plunger. Foam dispensed after the initial quantity of poor quality foam is stored in the main barrel of the syringe ready for administration to a patient in need of treatment. | 04-12-2012 |
| 20120082716 | Cytotoxic agents - A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterised in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′ and 5′ ends of the DNA, that is unbasepaired with another base in a form that is capable of being internalised by the cell. | 04-05-2012 |
| 20120071548 | Therapeutic compositions - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 03-22-2012 |
| 20120035736 | Tibial component - A tibial knee joint prosthesis for attachment to a suitably prepared tibial bone, providing bearing portions in the lateral and medial compartments. The lateral and medial bearing surfaces of the component are inclined at different angles in the anterior to posterior direction of the knee, so that when mounted to the tibia, the lateral bearing surface of the prosthesis is higher than the medial bearing surface to the posterior side of the knee. In this way the lateral ligament is tightened progressively more than the medial ligament as the knee moves from extension to flexion, resulting in increased stability in the lateral compartment. | 02-09-2012 |
| 20120015947 | Cyclic hydroxylamine as psychoactive compounds - A compound of formula (I): | 01-19-2012 |
| 20110288288 | Process for the preparation of 17-0-vinyl- triflates as intermediates - A compound of formula (I) or a pharmaceutically-acceptable salt thereof, may be made by a process including a triflating step by which a ketone of formula (II) is converted into a triflate of formula (III) in the presence of a base comprising a tertiary or heterocyclic amine such that the pK | 11-24-2011 |
| 20110184063 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both γ-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of γ-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of γ-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-β1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-β1/TNF-α ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as γ-linolenic acid. | 07-28-2011 |
| 20110152209 | Core 2 GlcNAc-T Inhibitors - The present invention relates to the use of known and novel compounds as inhibitors of UDP-GlcNAc:Galβ1,3GalNAc-R (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyl transferase (core 2 β1,6 N-acetylaminotransferase, core 2 GlcNAc-T-EC 2.4.1.102). Such inhibitors have applications in therapy for diseases associated with raised activity of core 2 GlcNAc-T, in particular inflammatory diseases, atherosclerosis, diabetic cardiomyopathy, cancers—including treatment or prevention of metastasis—or diabetic retinopathy. | 06-23-2011 |
| 20110065656 | DOPAMINERGIC MIMETICS - A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM. | 03-17-2011 |
| 20110024448 | Apparatus and method for dispensing foam - A foam transfer device is described, for use with aerosol canister apparatus for producing a sclerosant foam for the treatment of, inter alia, varicose veins. The device enables diversion of an initial quantity of below-specification foam from the canister to waste, e.g. to an integral waste chamber, before dispensing a further quantity of foam for use in treatment. The switching of the flow from the waste chamber to a different outlet for use is accomplished without interrupting the flow from the aerosol canister since this would cause the foam to drop below specification again. The waste chamber may be transparent so that the foam entering it can be observed and a decision made by a user when to stop diverting foam to waste. Alternatively, the foam may be diverted automatically e.g. when a set time has elapsed or a set volume of foam dispensed. The foam for use is normally dispensed into a syringe for subsequent injection into a varicose vein of a patient. | 02-03-2011 |
| 20100297196 | Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R | 11-25-2010 |
| 20100260007 | Preparation of therapeutic foam - Closed pouch comprising a wall defining an enclosed space containing carbon dioxide, and a pair of syringes contained within the enclosed space. The syringes are connected together by a syringe connector, and of the syringes contains a gas or gas mixture other than air, while the other contains a foamable liquid. Breakage of the syringe, connector and pumping of the syringes produces a foam useful in the treatment of varicose veins. | 10-14-2010 |
| 20100216824 | Anti-cancer cyclopenta [G]quinazonline compounds - Cyclopenta[g]quinazolines of the formula (I):— | 08-26-2010 |
| 20100178486 | Process for fabricating polypropylene sheet - A process for production of a monolithic article from a web of fibres of oriented polypropylene homopolymer or copolymer having a weight average molecular weight (M | 07-15-2010 |
| 20100152437 | Methanesulfonate salts of abiraterone-3-esters and recovery of salts of abirater one-3-esters from solution in methyl tert-butyl ether - A salt of a compound of formula (I) may be made with methanesulfonic acid. The salt and salts with other acids may be prepared by recovering from methyl tert-butyl ether (MTBE). | 06-17-2010 |
| 20100131071 | Tibial component - A tibial knee joint prosthesis for attachment to a suitably prepared tibial bone, providing bearing portions in the lateral and medial compartments. The lateral and medial bearing surfaces of the component are inclined at different angles in the anterior to posterior direction of the knee, so that when mounted to the tibia, the lateral bearing surface of the prosthesis is higher than the medial bearing surface to the posterior side of the knee. In this way the lateral ligament is tightened progressively more than the medial ligament as the knee moves from extension to flexion, resulting in increased stability in the lateral compartment. | 05-27-2010 |
| 20100113810 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |
| 20100113595 | Treatment of neurodegenerative conditions - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 05-06-2010 |
| 20100081711 | Cytotoxic agents - A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterised in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′ and 5′ ends of the DNA, that is unbasepaired with another base in a form that is capable of being internalised by the cell. | 04-01-2010 |
| 20100048496 | Core 2 GlcNAc-T inhibitors - A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of formula I to a patient in need thereof | 02-25-2010 |
| 20100048495 | Core 2 GlcNAc-T inhibitors III - A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of the formula I to a patient in need thereof | 02-25-2010 |
| 20090312329 | Cyclic hydroxylamine as psychoactive compounds - A compound of formula (I): in which X represents O or CH | 12-17-2009 |
| 20090253781 | Therapeutic compositions - Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions. | 10-08-2009 |
| 20090149444 | Benzylamine analogues - A compound of the formula (I): | 06-11-2009 |
| 20090124961 | Aerosol Valve - A steam-sterilizable aerosol valve has a valve body of polymeric material such as polyphenylene sulfone (PPSU) having an HDT (heat deflection temperature) at 1.8 MPa stress in the range of 200-275° C. Such a valve has the ability to survive steam sterilization without significant degradation of properties or appearance. | 05-14-2009 |
| 20090036410 | Structured Phospholipids - A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of γ-linolenoyl, dihomo-γ-linolenoyl acid and arachidonoyl. | 02-05-2009 |
| 20090023760 | Anti-cancer cyclopenta[G]quinazoline compounds - Cyclopenta[g]quinazolines of the formula (I): wherein: A is a group OR or NR | 01-22-2009 |
| 20090005402 | Medicine containing pyrimidine derivative - A drug for central diseases which contains a compound represented by general formula (I), or a pharmacologically acceptable salt thereof, as active component | 01-01-2009 |
| 20080255095 | Benzylamine analogues - A compound of the formula (I): | 10-16-2008 |
